Exenatide

• •First 1 to 4 weeks: nausea and reduced appetite are common while the body adjusts; the low 5 mcg starter dose is used to ease this in

• •Weeks 4 to 8: on the full dose, appetite suppression and post-meal glucose control are most noticeable and early weight loss begins

• •For the once-weekly extended-release form, blood levels and full effect build gradually over about 6 to 7 weeks

• •Gastrointestinal side effects usually lessen over time; small injection-site nodules can appear with the weekly form

• •Weight and glucose effects are modest compared with newer agents such as [semaglutide](/compound/semaglutide) or [tirzepatide](/compound/tirzepatide)

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Exenatide is one of the most extensively studied GLP-1 receptor agonists, with a clinical record stretching back to the AMIGO program of the mid-2000s and dozens of randomized trials since. Note: these are human trials in people with type 2 diabetes (or, in one case, non-diabetic obesity); this summary is educational and research-use-only.

Twice-daily (Byetta): In a 26-week head-to-head trial against insulin glargine, exenatide 10 mcg twice daily lowered HbA1c by 1.1 percent (matching glargine) while producing a 2.3 kg weight loss versus a 1.8 kg gain on insulin. Nausea was far more common on exenatide (57 percent vs 9 percent) [PMID:16230722].

Once-weekly (Bydureon): DURATION-1 compared the extended-release 2 mg weekly formulation with the twice-daily version over 30 weeks. The weekly dose cut HbA1c more (-1.9 percent vs -1.5 percent) with similar weight loss and no extra hypoglycemia [PMID:18782641]. A pooled analysis of seven phase 3 trials (1,719 patients) confirmed consistent HbA1c, fasting-glucose, and weight improvements across age, sex, race, and BMI subgroups; the main side effects were gastrointestinal [PMID:22925173].

Head-to-head vs other GLP-1s: In DURATION-6, once-weekly exenatide was slightly less effective than daily liraglutide 1.8 mg (HbA1c -1.28 percent vs -1.48 percent) but caused less nausea, vomiting, and diarrhea [PMID:23141817]. In SUSTAIN 3, once-weekly semaglutide 1.0 mg clearly outperformed exenatide extended-release on both glucose (-1.5 percent vs -0.9 percent HbA1c) and weight (-5.6 kg vs -1.9 kg); injection-site reactions were more common with exenatide extended-release [PMID:29246950].

Cardiovascular safety: EXSCEL, a 14,752-patient outcomes trial, found once-weekly exenatide was safe for major cardiovascular events but did not significantly reduce them (hazard ratio 0.91, p=0.06 for superiority) [PMID:28910237].

Combination and non-diabetic use: Twice-daily exenatide has been added to basal insulin to improve control without the weight gain of prandial insulin [PMID:23061886]. In non-diabetic adults with obesity, a randomized trial showed exenatide 10 mcg twice daily cut food intake but did not change energy expenditure, and the weight difference versus placebo was not statistically significant at 24 weeks - a reminder that its weight effect on its own is modest [PMID:29596853].

Gastrointestinal effects are by far the most common: nausea (reported in roughly 40 to 57 percent of patients on the twice-daily form, usually worst early and fading over weeks), vomiting, diarrhea, constipation, and dyspepsia. Reduced appetite is expected. Other reported effects include headache, dizziness, jitteriness, and injection-site reactions - small subcutaneous nodules are especially common with the extended-release (weekly) formulation. Hypoglycemia is uncommon with exenatide alone but rises when it is combined with a sulfonylurea or insulin. Less common but serious concerns include acute pancreatitis, gallbladder disease, and acute kidney injury (usually linked to dehydration from nausea or vomiting). The extended-release product carries a boxed warning for thyroid C-cell tumors based on rodent studies.